title: The possible risk of lower-limb sclerotherapy causing an extended hypercoagulable state.
abstract: The risk of thrombosis after lower-extremity sclerotherapy is still an unresolved issue. This study was conducted to investigate the influence of sclerotherapy on coagulation and fibrinolysis by examining 20 patients who underwent surgical procedures, 10 of whom were treated by surgery alone (control group), while the other 10 were given sclerotherapy using 1% hydroxypolyaetoxydodecan as polidocanol (sclerotherapy group). Sex, age, and severity of disease was comparable between the two groups. No significant difference was found in the transient elevation of acute phase proteins, C-reactive protein (CRP), or fibrinogen. Thrombin antithrombin III complex (TAT), a marker of coagulation, transiently increased following treatment. In the control group, TAT peaked 3 days after treatment, whereas in the sclerotherapy group the elevation was prolonged, peaking 7 days after treatment. Elevation of the markers of fibrinolysis, plasmin plasmin inhibitor complex (PIC) and fibrin degradation products (FDP), was slower than that of TAT, peaking 7 days after treatment in both groups, the plasma PIC being significantly enhanced 7 days after treatment in the sclerotherapy group. A significant decrease in the platelet count was observed 3 days after treatment in the sclerotherapy group. These results suggest that sclerotherapy may enhance coagulation or fibrinolysis after surgical procedures.
authors.affiliation: Department of Surgery, Shiten-nohji Hospital, Osaka, Japan.
authors.forename: H
authors.initials: H
authors.lastname: Ariyoshi
authors.forename: J
authors.initials: J
authors.lastname: Kambayashi
authors.forename: S
authors.initials: S
authors.lastname: Tominaga
authors.forename: T
authors.initials: T
authors.lastname: Hatanaka
mesh_terms: D000328:Adult; D000368:Aged; D000990:Antithrombin III / Q000032:analysis; D001777:Blood Coagulation; D005260:Female; D005342:Fibrinolysis; D006801:Humans; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D015911:Sclerotherapy / Q000009:adverse effects*; D013927:Thrombosis / Q000209:etiology*; D016896:Treatment Outcome; D014648:Varicose Veins / Q000503:physiopathology / Q000628:therapy*
chemical_list: D000990:Antithrombin III